Cagrilintide 5mg
Long-Acting Amylin Analogue for Weight Loss and Satiety Research
Cagrilintide is a long-acting amylin analogue that reduces food intake and body weight via central amylin receptor activation. Combined with semaglutide in CagriSema, it achieves up to 25% weight loss in clinical trials.
Long-Acting Amylin Analogue for Weight Loss and Satiety Research
Cagrilintide activates amylin receptors (CALCR/RAMP) in the area postrema and hypothalamus to reduce gastric emptying, suppress glucagon, and enhance satiety — a distinct mechanism from GLP-1 that produces additive weight loss when combined.
As one of the most studied compounds in the metabolic & fat loss research space, Cagrilintide has attracted sustained scientific interest across Amylin receptor research, Combination weight loss studies, Satiety mechanism research. Peer-reviewed evidence indicates that cagriSema achieves ~25% weight loss in Phase 2, which has positioned Cagrilintide as a reference standard for researchers exploring amylin receptor research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Cagrilintide Documented Benefits: 3 Documented Mechanisms
Amylin Receptor Activation
Activates CALCR/RAMP amylin receptors to reduce food intake via distinct pathways from GLP-1.
Synergy with Semaglutide
CagriSema combination achieves ~25% weight loss — potentially superior to either alone.
Glucagon Suppression
Reduces glucagon secretion alongside GLP-1 for enhanced glycemic control.
How Cagrilintide Works: Molecular Mechanism & Pathway
Long-acting amylin analogue activating CALCR/RAMP1 and RAMP3 receptors in the brainstem and hypothalamus for satiety, reduced gastric emptying, and glucagon suppression.
The 3 primary research pathways identified for Cagrilintide — Amylin Receptor Activation, Synergy with Semaglutide, Glucagon Suppression — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that distinct amylin mechanism additive to GLP-1, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Cagrilintide's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Cagrilintide is routinely studied alongside Semaglutide and Cagrilintide in metabolic & fat loss-focused compound panels. Researchers investigating amylin receptor research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that long 7-day half-life enabling once-weekly dosing research has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Cagrilintide research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- CagriSema achieves ~25% weight loss in Phase 2
- Distinct amylin mechanism additive to GLP-1
- Long 7-day half-life enabling once-weekly dosing research
Ideal For
- Amylin receptor research
- Combination weight loss studies
- Satiety mechanism research
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Cagrilintide. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
CagriSema achieves ~25% weight loss in Phase 2
Distinct amylin mechanism additive to GLP-1
Long 7-day half-life enabling once-weekly dosing research
Third-Party Verified Every Batch
Each vial of Cagrilintide is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
